Insider Trading (Form 4)
NASDAQ
Telix Pharmaceuticals MD & Group CEO Christian Behrenbruch acquired 67,935 shares, signaling strong internal confidence in the company's trajectory.
Better than expected
NASDAQ
Telix Pharmaceuticals Ltd's Group CFO, Darren Charlton Smith, acquired 1,111 ordinary shares through the exercise of vested share rights.
Schedule 13G - Passive Investments
NASDAQ
SCHEDULE 13G: Telix Pharmaceuticals: Dr. Christian Behrenbruch and Family Trust Disclose 6.97% Passive Stake
Dr. Christian Behrenbruch, along with Elk River Holdings Pty Ltd, has disclosed a combined beneficial ownership of 6.97% of Telix Pharmaceuticals Ltd's ordinary shares, primarily held through a family trust, as a passive investment.
NASDAQ
SCHEDULE 13G: German Investor Dr. Andreas Kluge and Gnosis Verwaltungsgesellschaft Disclose 6.78% Stake in Telix Pharmaceuticals
Dr. Andreas Kluge and Gnosis Verwaltungsgesellschaft m.b.H. have jointly reported a beneficial ownership of 6.78% in Telix Pharmaceuticals Ltd, totaling 22,675,000 ordinary shares, as of November 12, 2024.